Drug Profile
Epoetin delta
Alternative Names: Dynepo; GA-EPO; Gene-activated epoetin alfa; Gene-activated epoetin alpha; Gene-activated erythropoietin; HMR 4396; MDL 104396; Recombinant human erythropoietin δLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis; Shire Pharmaceuticals Group
- Developer sanofi-aventis; Shire; Shire plc
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Anaemia
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 31 Dec 2008 Discontinued - Registered for Anaemia in European Union (IV)
- 31 Dec 2008 Discontinued - Registered for Anaemia in European Union (SC)